41 related articles for article (PubMed ID: 32482107)
1. Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia.
Ruiz-Llobet A; Gassiot S; Sarrate E; Zubicaray J; Rives S; Suleman W; Berrueco R
Thromb Haemost; 2024 May; ():. PubMed ID: 38684189
[TBL] [Abstract][Full Text] [Related]
2. Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
Tölle M; Gökbuget N; Habringer S; Keller U; Schwartz S
Ann Hematol; 2024 May; ():. PubMed ID: 38733396
[No Abstract] [Full Text] [Related]
3. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Burke PW; Hoelzer D; Park JH; Schmiegelow K; Douer D
ESMO Open; 2020 Oct; 5(5):e000858. PubMed ID: 33037033
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
Advani AS; Larsen E; Laumann K; Luger SM; Liedtke M; Devidas M; Chen Z; Yin J; Foster MC; Claxton D; Coffan K; Tallman MS; Appelbaum FR; Erba H; Stone RM; Hunger SP; McNeer JL; Loh ML; Raetz E; Winick N; Carroll W; Larson RA; Stock W
Blood Adv; 2021 Jan; 5(2):504-512. PubMed ID: 33496745
[TBL] [Abstract][Full Text] [Related]
5. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B; Zhao Q; Walker AR; Mims AS; Vasu S; Long M; Z Haque T; Blaser BW; Grieselhuber NR; Wall SA; Behbehani GK; Blachly JS; Larkin K; Byrd JC; Garzon R; Wang TF; Bhatnagar B
Int J Hematol Oncol; 2020 Sep; 9(3):IJH28. PubMed ID: 33014332
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
[TBL] [Abstract][Full Text] [Related]
7. D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.
Anderson DR; Stock W; Karrison TG; Leader A
Blood Adv; 2022 Sep; 6(17):5146-5151. PubMed ID: 35728059
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form.
Hu Z; Persaud Y; Ahuja S
Crit Rev Oncol Hematol; 2024 May; 197():104347. PubMed ID: 38583546
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
14. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
